Hansa Biopharma to Participate in UBS Global Healthcare Conference and RBC Capital Markets Global Healthcare Conference in New York City

LUND, Sweden, May 13, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company's management team will participate in the following upcoming investor conferences:

The UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019, with a presentation at 10:00AM ET/ 4:00PM CET.

The 2019 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, May 21, 2019.

A live webcast of the UBS presentation will be available on the Events & Webcast page of the Company's website, www.hansabiopharma.com.

A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on March 13, 2019.

For further information, please contact:

Company:
Rolf Gulliksen, Head of Corporate Communications
Hansa Biopharma
Mobile: +46(0)733-328 634
E-mail: rolf.gulliksen@hansabiopharma.com 

Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46(0)709-298 269
E-mail: klaus.sindahl@hansabiopharma.com

Swedish Investor and Media Relations:

Cord Communications
Mikael Widell
+46-70-311 99 60
U.S. Investor and Media Relations:

Argot Partners
Stephanie Marks / David Rosen (media)
+1-212-600-1902

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-participate-in-ubs-global-healthcare-conference-and-rbc-capital-markets-global-he,c2811925

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/hansa-biopharma-to-participate-in-ubs-global-healthcare-conference-and-rbc-capital-markets-global-healthcare-conference-in-new-york-city-300848667.html

SOURCE Hansa Biopharma AB